CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strainStudy initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in …
Jetzt den vollständigen Artikel lesen